AstraZeneca's Lynparza gains additional breast cancer indication in Canada
Leon Neal         

Health Canada has approved LynparzaÂ (olaparib) as an adjuvant treatment for germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer.
The approval is for patients who have been treated with neoadjuvant or adjuvant chemotherapy and confirmedÂ germline BRCA mutation.
The approval was based on the agency's accelerated review pathway and results from the OlympiA Phase III trial that showed a reduction in the risk of invasive breast cancer recurrences, second cancers or death by 42% compared to placebo.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu (trastuzumab deruxtecan)Â was recently approved by the U.S. FDA for HER2-low breast cancer.